Clin2
NCT06816810Possibly a fitNot yet recruiting

Hydroxychloroquine for early Parkinson's disease

Parkinson&Amp;#39;s Disease

Treatments studied

Part of Brain & nervous system clinical trials.

This study tests whether hydroxychloroquine can slow the progression of Parkinson's disease. It is for people who have been diagnosed with Parkinson's within the last 4 years and are not yet in advanced stages.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
40 people
Ages
35 years to 80 years
Study type
Interventional

Who can take part

  • You are between 35 and 80 years old.
  • You have had Parkinson's disease for at least 6 months but no more than 4 years, confirmed by a neurologist.
  • Your Parkinson's symptoms are mild to moderate (Hoehn and Yahr stage 2 or less).
  • You have been on the same Parkinson's medications for at least 30 days and expect to stay on them for about a year.
  • You do not have severe motor fluctuations or disabling involuntary movements.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07280299Not yet recruiting· Phase 2
Study of GT-02287 for early Parkinson's disease

This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.

NCT07781644Not yet recruiting· Phase 1/Phase 2
Testing a new drug for early Parkinson's disease

This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.

NCT07157345Recruiting· Phase 1
Testing PDR-001 for Parkinson's Disease

This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.

Shanghai, Shanghai Municipality
NCT07157735Recruiting· Phase 2
Testing an anti-inflammatory drug for early Parkinson's disease

This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.

Cambridge
NCT06976268Recruiting· Phase 2/Phase 3
Testing BHV-8000 for early Parkinson's disease

This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.

Birmingham, Alabama
NCT07741045Not yet recruiting· Phase 3
New oral treatment for early-onset Parkinson's

This trial tests a new oral medication for people with early-onset Parkinson's disease. It aims to see if the drug safely improves motor symptoms and quality of life compared to a placebo.

Beijing, Beijing Municipality

Hear when a new Parkinson&Amp;#39;s Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.